Is NTRB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NTRB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NTRB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NTRB's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NTRB?
Key metric: As NTRB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for NTRB. This is calculated by dividing NTRB's market cap by their current
revenue.
What is NTRB's PS Ratio?
PS Ratio
29.3x
Sales
US$1.80m
Market Cap
US$52.71m
NTRB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Sales vs Industry: NTRB is expensive based on its Price-To-Sales Ratio (29.3x) compared to the US Pharmaceuticals industry average (2.9x).
Price to Sales Ratio vs Fair Ratio
What is NTRB's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
NTRB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
29.3x
Fair PS Ratio
n/a
Price-To-Sales vs Fair Ratio: Insufficient data to calculate NTRB's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.